Here are the staff publications for November 2019.
Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 2nd December 2019.
1. Ahn SH, Yeo AU, Kim KH, Kim C, Goh Y, Cho S, Lee SB, Lim YK, Kim H, Shin D, Kim T, Kim TH, Youn SH, Oh ES, Jeong JH. Comparative clinical evaluation of atlas and deep-learning-based auto-segmentation of organ structures in liver cancer. Radiation Oncology 2019;14:213.
2. Bergin ART, Luen SJ, Savas P, Boolell V, Cho D, Lynch J, Nott L, Stuart-Harris R, Teo LN, Yap SY, Loi S. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. Asia-Pacific Journal of Clinical Oncology 2019;15:377-82.
3. Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer 2020;146:161-8.
4. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., Psyrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonzalez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394:1915-28.
5. Butcher G, Howard H, Sathianathen N, Catto JWF, Murphy DG. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. European Urology 2019;76:872-3.
6. Campbell BA, Ryan G, McCormack C, Tangas E, Bressel M, Twigger R, Buelens O, van der Weyden C, Prince HM. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. Cancers 2019;11:e1758.
7. Chen Z, Wang H, D'Souza C, Koay HF, Meehan B, Zhao Z, Pediongco T, Shi M, Zhu T, Wang B, Kjer-Nielsen L, Eckle SBG, Rossjohn J, Fairlie DP, Godfrey DI, Strugnell RA, McCluskey J, Corbett AJ. Characterization and Purification of Mouse Mucosal-Associated Invariant T (MAIT) Cells. Current Protocols in Immunology 2019;127:e89.
8. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-Leon DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild M, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases 2019;19:e405-e21.
9. De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European Urology 2019;76:732-9.
10. Edbrooke L, Denehy L, Granger CL, Kapp S, Aranda S. Home-based rehabilitation in inoperable non-small cell lung cancer-the patient experience. Supportive Care in Cancer 2020;28:99-112.
11. Fennell KA, Bell CC, Dawson MA. Epigenetic therapies in acute myeloid leukemia: where to from here? Blood 2019;134:1891-901.
12. Haupt S, Caramia F, Herschtal A, Soussi T, Lozano G, Chen H, Liang H, Speed TP, Haupt Y. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. Nature Communications 2019;10:5385.
13. Henderson MA, Gyorki D, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. Annals of Surgical Oncology 2019;26:4663-72.
14. Hicks RJ, Iravani A, Sandhu S. (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond. PET Clinics 2020;15:11-22.
15. Hilton-Proctor JP, Ilyichova O, Zheng Z, Jennings IG, Johnstone RW, Shortt J, Mountford SJ, Scanlon MJ, Thompson PE. Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. Bioorganic & Medicina Chemistry 2019;27:115157.
16. Ierano C, Thursky K, Peel T, Rajkhowa A, Marshall C, Ayton D. Influences on surgical antimicrobial prophylaxis decision making by surgical craft groups, anaesthetists, pharmacists and nurses in public and private hospitals. PloS One 2019;14:e0225011.
17. Koh J, Walsh P, D'Costa I, Bhatti O. Head and neck squamous cell carcinoma survivorship care. Australian Journal of General Practice 2019;48:846-8.
18. Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: An update on diagnosis and management. Australian Journal of General Practice 2019;48:826-31.
19. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, Odunsi K, Steed H, Herpel E, Anglesio MS, Zhang B, Lambie N, Swerdlow AJ, Lubinski J, Vierkant RA, Goode EL, Menon U, Toloczko-Grabarek A, Oszurek O, Bilic S, Talhouk A, Garcia-Closas M, Wang Q, Tan A, Farrell R, Kennedy CJ, Jimenez-Linan M, Sundfeldt K, Etter JL, Menkiszak J, Goodman MT, Klonowski P, Leung Y, Winham SJ, Moysich KB, Behrens S, Kluz T, Edwards RP, Gronwald J, Modugno F, Hernandez BY, Chow C, Kelemen LE, Keeney GL, Carney ME, Natanzon Y, Robertson G, Sharma R, Gayther SA, Alsop J, Luk H, Karpinskyj C, Campbell I, Sinn P, Gentry-Maharaj A, Coulson P, Chang-Claude J, Shah M, Widschwendter M, Tang K, Schoemaker MJ, Koziak JM, Cook LS, Brenton JD, Daley F, Kristjansdottir B, Mateoiu C, Larson MC, Harnett PR, Jung A, deFazio A, Gorringe KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Kobel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology 2019;32:1834-46.
20. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology 2019;94:1353-63.
21. Nan Tie E, Na LH, Hicks RJ, Spillane J, Speakman D, Henderson MA, Gyorki DE. The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. Annals of Surgical Oncology 2019;26:4673-80.
22. Olafson LR, Siddell AH, Field KM, Byrnes M, Rapkins RW, Ng B, Nixdorf S, Barnes EH, Johns TG, Yip S, Simes J, Nowak AK, Rosenthal MA, McDonald KL. Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. Journal of Clinical Neuroscience 2019;70:157-63.
23. Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, Beavis PA, House IG, Van Audernaerde JR, Darcy PK, Kershaw MH, Slaney CY. Tissue-specific tumor microenvironments influence responses to immunotherapies. Clinical & Translational Immunology 2019;8:e1094.
24. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadalo L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems M, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden A, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon YCT, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Ronlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology 2019;76:831-42.
25. Paige E, Thursky K, Slavin M. Mold-active prophylaxis in acute leukemia: not enough of a good thing?(). Leukemia and Lymphoma 2019;60:2851-3.
26. Partap S, Russo S, Esfahani B, Yeom K, Mazewski C, Embry L, Wheeler G, Ullrich NJ, Bowers DC. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. Pediatric Neurology 2019;101:2-10.
27. Pascoe M, Ski CF, Thompson DR, Linden T. Serum cholesterol, body mass index and smoking status do not predict long-term cognitive impairment in elderly stroke patients. Journal of the Neurological Sciences 2019;406:116476.
28. Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology 2019;51:673-80.
29. Peacock O, Waters PS, Otero de Pablos J, Boussioutas A, Skandarajah A, Simpson JA, Warrier SK, Heriot AG. A systematic review of risk-reducing cancer surgery outcomes for hereditary cancer syndromes. European Journal of Surgical Oncology 2019;45:2241-50.
30. Rudd-Schmidt JA, Hodel AW, Noori T, Lopez JA, Cho HJ, Verschoor S, Ciccone A, Trapani JA, Hoogenboom BW, Voskoboinik I. Lipid order and charge protect killer T cells from accidental death. Nature Communications 2019;10:5396.
31. Sathianathen NJ, Regmi S, Gupta S, Konety BR. Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer. Urologic Clinics of North America 2020;47:103-10.
32. Sun Y, Williams S, Byrne D, Keam S, Reynolds HM, Mitchell C, Wraith D, Murphy D, Haworth A. Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. British Journal of Radiology 2019;92:20190373.
33. Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood 2019;134:35.
34. Vardy JL, Chan RJ, Koczwara B, Lisy K, Cohn RJ, Joske D, Dhillon HM, Jefford M. Clinical Oncology Society of Australia position statement on cancer survivorship care. Australian Journal of General Practice 2019;48:833-6.
35. Waters PS, Peacock O, Warrier SK, Wakeman C, Eglinton T, Lynch AC, Frizelle FA, Heriot AG, McCormick J. Evolution of pelvic exenteration surgery- resectional trends and survival outcomes over three decades. European Journal of Surgical Oncology 2019;45:2325-33.
36. Zeinomar N, Knight JA, Genkinger JM, Phillips KA, Daly MB, Milne RL, Dite GS, Kehm RD, Liao Y, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, MacInnis RJ, Hopper JL, Terry MB. Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC). Breast Cancer Research 2019;21:128.